Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).
Publications
2 shownUpdated international consensus report on the investigation and management of primary immune thrombocytopenia
Abstract Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This a...
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 2
- Citations
- 981
- Institution
- Assistance Publique – Hôpitaux de Paris
External Links
Identifiers
- ORCID
- 0000-0002-9822-7400
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.